Lilly(Eli) & Co

NYSE:LLY   3:59:59 PM EDT
-0.61 (-0.43%)
4:00:00 PM EDT: $142.00 +0.23 (+0.16%)
Products, Regulatory

Lilly Statement On NIAID Decision To Pause Enrollment In Activ-3 Clinical Trial

Published: 10/14/2020 13:42 GMT
Eli Lilly and Co (LLY) - Lilly Statement on the Niaid Decision to Pause Enrollment in Activ-3 Clinical Trial.
Eli Lilly and Co - Pause Impacts the Activ-3 Study of a Lilly Neutralizing Antibody; All Other Studies Continue.
Eli Lilly - at This Time, Only Dsmb Has Reviewed Data From Activ-3 Trial, and Nih Leadership and Lilly Remain Blinded to Ongoing Trial Results.
Eli Lilly and Co- Dsmb Also Considered Impact of Activ-3 Study Pause on Activ-2 and Did Not Recommend Any Changes to That Study’s Design Or Enrollment.